Compliance Radar

Who was sanctioned, and for what?

Fines, court rulings and incidents from Europe and North America: 756 cases from 32 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.

25cases from 7 jurisdictions
€5.49bnTotal of monetary amounts (21 cases with an amount)
€4.75bnLargest single case: Purdue Pharma L.P.
€3.35mMedian per case with an amount

Click a bar to drill down one level.

When?

per quarter, by date of decision
Trend
PeriodCasesTotal
Q3 20230—
Q4 20231€13.4m
Q1 20240—
Q2 20241€18.8m
Q3 20240—
Q4 20242€464.4m
Q1 20252€957,452
Q2 20253€192.5m
Q3 20252€176,590
Q4 20251€200,913
Q1 20263€1.77m
Q2 20264€4.76bn
Q3 20266€31.9m

25 cases

10 Sep 2026 Dompé U.S. Inc.Dompé U.S.: 32 million USD – Medicare patients’ co-payments covered via foundations USAGifts, hospitality and benefits €27.5m

From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.

What organisations can take from it

Benefits flowing to customers via foundations or other third parties remain benefits provided by the company – donations to patient assistance programmes require strict independence.

Relevance to training and awareness

Benefits to patients and customers via third parties

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Mitigating circumstances
Self-disclosure.

Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

25 Aug 2026 ExxonMobil Chemical LimitedExxonMobil Chemical: 267,000 GBP for five hydrocarbon leaks at Fife ethylene plant United KingdomWorkplace safety and accidents €312,098

Between February 2018 and September 2019, five leaks of highly flammable hydrocarbons occurred at the Mossmorran major hazard site (COMAH upper tier), all caused by corrosion under insulation; around 82 tonnes escaped in one leak. During a routine inspection in May 2019, inspectors of the Health and Safety Executive (HSE) smelled escaping gas – the company had known about this leak for around four months and had continued production without additional precautions. The inspection arrangements for insulated pipework were inadequate; fine of 267,000 GBP.

What organisations can take from it

Recurring damage patterns must change the inspection concept – visual inspections from the ground are not sufficient for insulated pipework.

Authority / court
Health and Safety Executive (Kirkcaldy Sheriff Court)
Area of law
Health and safety and employment law · Workplace safety and accidents
Legal basis
Provision and Use of Work Equipment Regulations 1998, reg. 6(2); Health and Safety at Work etc. Act 1974, s. 33(1)(c)
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
26 Aug 2026

Original amount 267,000 GBP, converted at the ECB reference rate of 25 Aug 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

14 Aug 2026 Henkel AG & Co. KGaAHenkel/Liquid Nails: court blocks takeover of Loctite’s main competitor USAMerger control Order

Henkel wanted to buy the construction adhesive brand Liquid Nails for 725 million USD from the financial investor American Industrial Partners, thereby taking over the main competitor of its Loctite brand. After a seven-day trial, the federal court, on application by the Federal Trade Commission (FTC), issued a permanent injunction against the acquisition.

What organisations can take from it

Acquiring the closest competitor carries a high risk of prohibition, even at a moderate deal volume.

Authority / court
U.S. District Court for the Southern District of New York (auf Antrag der FTC)
Area of law
Competition law · Merger control
Legal basis
Section 7 Clayton Act; Section 13(b) FTC Act (Permanent Injunction)
Action
Order
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
17 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

10 Aug 2026 Veloxis Pharmaceuticals Inc.Veloxis: over 46 million USD – luxury trips, dinners and gifts for transplant teams USAGifts, hospitality and benefits Other

From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.

What organisations can take from it

Invitations and gifts to decision-makers must not only be limited but also fully reported to transparency registers.

Relevance to training and awareness

Gifts, travel and hospitality for healthcare professionals; transparency reporting

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

3 Aug 2026 Guangxi Kelun Pharmaceutical Co., Ltd.UFLPA list: antibiotics manufacturer Guangxi Kelun Pharmaceutical added USAForced and child labour Order

The U.S. Forced Labor Enforcement Task Force (FLETF) listed the manufacturer of cephalosporin antibiotics because it sources antibiotic intermediates from Yili Chuanning Biotechnology in Xinjiang. The company's goods are therefore presumed to have been produced with forced labour on import into the US unless the importer rebuts this.

What organisations can take from it

Pharmaceutical companies must be able to trace their supply chains back to active ingredient intermediates.

Authority / court
U.S. Department of Homeland Security (Forced Labor Enforcement Task Force)
Area of law
Supply chain and human rights · Forced and child labour
Legal basis
Uyghur Forced Labor Prevention Act, Section 2(d)(2)(B)(v)
Action
Order
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Published
3 Aug 2026

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

20 Jul 2026 EyePoint Pharmaceuticals, Inc.EyePoint: 4.66 million USD – kickbacks to surgery centres for purchasing an eye medicine USACommercial bribery €4.08m

Between January 2019 and March 2023, the pharmaceutical manufacturer allegedly paid kickbacks to ambulatory surgery centres to induce them to purchase and use the injectable drug DEXYCU for cataract surgery. To resolve the False Claims Act allegations, EyePoint paid 4,657,463.18 USD and entered into a Corporate Integrity Agreement with HHS-OIG.

What organisations can take from it

Discounts, payments or services to institutions that make purchasing decisions require a documented consideration at market value.

Relevance to training and awareness

Granting benefits to customers and purchasing decision-makers

Authority / court
U.S. Department of Justice
Area of law
Bribery and corruption · Commercial bribery
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals

Original amount 4,657,463.18 USD, converted at the ECB reference rate of 20 Jul 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

14 May 2026 Takeda Pharmaceuticals U.S.A., Inc.Takeda: 13.7 million USD – speaker fees and luxury meals for prescribing physicians USAGifts, hospitality and benefits €11.7m

From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.

What organisations can take from it

Speaker programmes need a demonstrable educational purpose – repeated attendance and expensive hospitality turn them into inducements.

Relevance to training and awareness

Invitations, hospitality and fees for healthcare professionals

Authority / court
U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more

Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

28 Apr 2026 Purdue Pharma L.P.Purdue Pharma: 5.544 billion USD penalty – including kickbacks via the speaker programme USAGifts, hospitality and benefits €4.75bn

Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.

What organisations can take from it

Fee programmes for customers who drive revenue can become part of a criminal overall scheme – with consequences that threaten the company’s existence.

Relevance to training and awareness

Speaker fees and benefits for prescribing physicians

Authority / court
U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Culpability
intentional

Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

21 Apr 2026 Industrial Chemicals LimitedIndustrial Chemicals: 3.8 million GBP after caustic soda burns – one leg amputated United KingdomWorkplace safety and accidents €4.37m

In 2019, an employee stepped into a puddle of caustic soda; his safety boots offered no protection, and his leg had to be amputated below the knee. In 2022, another worker suffered chemical burns during manual decanting. The Health and Safety Executive (HSE) found leaking pipes and valves, a lack of maintenance, no risk assessment for decanting and untested safety footwear; fine of 3.8 million GBP plus 124,748 GBP in costs.

What organisations can take from it

Leaks of hazardous substances are not a normal state of affairs – maintenance, spill management and tested protective equipment go hand in hand.

Relevance to training and awareness

Handling corrosive hazardous substances and PPE

Authority / court
Health and Safety Executive (Southwark Crown Court)
Area of law
Health and safety and employment law · Workplace safety and accidents
Legal basis
Control of Substances Hazardous to Health Regulations 2002, reg. 7(1)
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Published
24 Apr 2026

Original amount 3,800,000 GBP, converted at the ECB reference rate of 21 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

6 Apr 2026 Caroline J. Campbell (Beschäftigte der ImmunityBio, Inc.)ImmunityBio employee sells shares ahead of news of FDA delay USAMarket abuse and insider dealing €288,298

In May 2023, an employee of the biotech company sold 48,495 shares with knowledge of the non-public information that the FDA would delay approval of the medicine Anktiva; after the announcement, the share price fell by around 55 %. Under the settlement, she is paying 157,066.28 USD in disgorgement, 18,130.97 USD in interest and a civil penalty of 157,066.28 USD.

What organisations can take from it

Trading bans and blackout periods must be known to all employees with access to approval or trial data, not just to the management board.

Relevance to training and awareness

Insider trading ban for employees, handling of approval information

Authority / court
U.S. Securities and Exchange Commission (SEC)
Area of law
Capital markets and financial supervision · Market abuse and insider dealing
Legal basis
Section 10(b) Securities Exchange Act 1934, Rule 10b-5
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals

Original amount 332,263.53 USD, converted at the ECB reference rate of 2 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

28 Jan 2026 Syngenta LtdSyngenta: 400,000 GBP after uncontrolled release of high-pressure steam during maintenance United KingdomWorkplace safety and accidents €460,564

While flange bolts were being removed from a steam trap in November 2023, a corroded isolation valve failed and high-pressure steam escaped; the contractor's fitter narrowly escaped serious injury. The agrochemicals group had not maintained work equipment and had not assessed the risk despite known corrosion (only single instead of double isolation). The Health and Safety Executive (HSE) prosecution resulted in a fine of 400,000 GBP plus 8,288 GBP in costs.

What organisations can take from it

Known corrosion requires safer isolation procedures – routine tasks must not mask risks.

Relevance to training and awareness

Isolation and shut-off during maintenance

Authority / court
Health and Safety Executive (Leeds Magistrates' Court)
Area of law
Health and safety and employment law · Workplace safety and accidents
Legal basis
Provision and Use of Work Equipment Regulations 1998, reg. 5(1); Management of Health and Safety at Work Regulations 1999, reg. 3(1)
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
28 Jan 2026

Original amount 400,000 GBP, converted at the ECB reference rate of 28 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

13 Jan 2026 Estee Lauder Cosmetics Ltd.Estee Lauder Cosmetics: 750,000 CAD fine for unreported PFAS in eyeliners Canada, ONWaste and hazardous substances €463,765

A routine inspection in 2023 found that the company was selling eyeliners containing the PFAS substance perfluorononyl dimethicone without submitting the required notification of a ‘significant new activity’; a subsequent compliance order was not complied with. The court imposed 750,000 CAD; the company must inform its shareholders and is listed in the Environmental Offenders Registry.

What organisations can take from it

Product development and regulatory affairs must check new substances for notification requirements before market launch; regulatory orders must be implemented within the deadline.

Relevance to training and awareness

Chemical notification and approval obligations for product launches

Authority / court
Ontario Court of Justice (Ermittlungen: Environment and Climate Change Canada)
Area of law
Environment and sustainability · Waste and hazardous substances
Legal basis
Canadian Environmental Protection Act, 1999 (Significant New Activity, Compliance Order)
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Published
2 Feb 2026

Original amount 750,000 CAD, converted at the ECB reference rate of 13 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

7 Jan 2026 Superior General Partner Inc.Superior General Partner: 1.35 million CAD fine for sodium chlorite in river and late reporting Canada, QCWaste and hazardous substances €845,987

In 2019, as a result of an equipment defect, sodium chlorite entered the Rivière du Lièvre twelve times from the ERCO Mondial chemical plant in Gatineau; in the last incident, the authorities were only informed after five days. The company was fined 1.35 million CAD, and the then technical and environmental director 15,000 CAD.

What organisations can take from it

Reporting obligations for releases of substances apply immediately; those who wait for days incur additional liability – including personally as the person responsible.

Relevance to training and awareness

Immediate reporting of environmental incidents to the authorities

Authority / court
Court of Québec (Ermittlungen: Environment and Climate Change Canada)
Area of law
Environment and sustainability · Waste and hazardous substances
Legal basis
Fisheries Act (Einbringen schädlicher Stoffe; unterlassene sofortige Meldung)
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Liability of senior managers
Jean-François Roux, the plant's then technical and environmental director, was personally fined 15,000 CAD.
Published
8 Jan 2026

Original amount 1,365,000 CAD, converted at the ECB reference rate of 7 Jan 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

28 Oct 2025 ExxonMobil Chemical LimitedExxonMobil Chemical: 176,000 GBP fine for six days of continuous flaring in Fife United KingdomEmissions and permits €200,913

Following a loss of steam in April 2019, the ethylene plant in Fife flared for almost a week; the smoke significantly exceeded permit limits, and the Scottish Environment Protection Agency (SEPA) received over 900 complaints. Existing procedures and emergency plans should have prevented the incident but were not adequately followed. The company pleaded guilty and was fined 176,000 GBP.

What organisations can take from it

Emergency plans only protect if staff apply them consistently in an emergency – regular drills are part of permit compliance.

Relevance to training and awareness

Compliance with operating and emergency procedures in industrial plants

Authority / court
Kirkcaldy Sheriff Court (Ermittlungen: Scottish Environment Protection Agency, SEPA)
Area of law
Environment and sustainability · Emissions and permits
Legal basis
Regulation 67(1)(b) Pollution Prevention and Control (Scotland) Regulations 2012; Section 2 Pollution Prevention and Control Act 1999
Action
Fine
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Culpability
negligent
Published
28 Oct 2025

Original amount 176,000 GBP, converted at the ECB reference rate of 28 Oct 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

10 Sep 2025 Colorcon LimitedPharmaceutical supplier Colorcon paid Moscow salaries via sanctioned banks United KingdomBreaches of sanctions and embargoes €176,590

In 2022, the Moscow office of the British subsidiary made payments – mainly salaries – to accounts at Alfa-Bank, Promsvyazbank, Sberbank and VTB; after deduction of payments covered by a general licence, around 128,300 GBP remained in breach. The approval process in the UK checked only the amount and the recipient, not the bank; because of a four-month delay in reporting, HM Treasury's Office of Financial Sanctions Implementation (OFSI) granted only a 35% instead of a 50% reduction.

What organisations can take from it

Anyone approving payments must also screen the recipient's bank against sanctions lists – and report breaches discovered without delay.

Relevance to training and awareness

Payment approval with screening of the recipient bank, prompt reporting

Authority / court
HM Treasury, Office of Financial Sanctions Implementation (OFSI)
Area of law
Sanctions and export control · Breaches of sanctions and embargoes
Legal basis
Russia (Sanctions) (EU Exit) Regulations 2019, reg. 12
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Mitigating circumstances
Disclosure and full cooperation, but delayed
Published
30 Sep 2025

Original amount 152,750 GBP, converted at the ECB reference rate of 10 Sep 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

25 Jul 2025 Tamro Eesti OÜTamro Eesti: order against unfair payment terms for food supplements EstoniaAbuse of market power Order

In consignment agreements, the pharmaceutical wholesaler had made payment to suppliers of food supplements dependent on subsequent resale (payment period over 30 days) and had reserved the right to hold suppliers liable for spoiled goods. The Konkurentsiamet (Estonian Competition Authority) found infringements of the act on unfair trading practices in the food supply chain and ordered amended contractual terms.

What organisations can take from it

Purchasing terms in the food sector – including for food supplements – must comply with the 30-day payment period and the prohibition on shifting risk.

Authority / court
Konkurentsiamet (Estnische Wettbewerbsbehörde)
Area of law
Competition law · Abuse of market power
Legal basis
§ 4 Abs. 1 und 2, § 5 Abs. 2, § 7 Abs. 1 PTEKS (UTP-Richtlinie (EU) 2019/633)
Action
Order
Status of proceedings
unknown
Sector
Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

16 Jun 2025 Unicat Catalyst Technologies, LLCCatalyst manufacturer Unicat supplied Iran and blocked Venezuelan company USABreaches of sanctions and embargoes €3.35m

In 2016–2021, the Texas supplier of catalysts for refineries and steelworks supplied products and advice to customers in Iran via its former CEO, employees and agents, and sold goods to a blocked Venezuelan company. The US Treasury's Office of Foreign Assets Control (OFAC) considered it an egregious but voluntarily self-disclosed case; there were parallel settlements with the DOJ and BIS, which were taken into account in determining the amount.

What organisations can take from it

When senior management itself steers embargo business, only independent controls and whistleblower channels help – voluntary self-disclosure after discovery reduces the penalty but does not prevent it.

Authority / court
U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)
Area of law
Sanctions and export control · Breaches of sanctions and embargoes
Legal basis
Iranian Transactions and Sanctions Regulations; Venezuela Sanctions Regulations; IEEPA
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Culpability
intentional
Mitigating circumstances
Voluntary self-disclosure, cooperation and remedial measures after discovery
Liability of senior managers
According to OFAC, the violations were carried out by the former CEO and co-founder as well as former employees.
Published
16 Jun 2025

Original amount 3,882,797 USD, converted at the ECB reference rate of 16 Jun 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

28 Apr 2025 Gilead Sciences, Inc.Gilead: 202 million USD – speaker programmes with fees, luxury meals and travel USAGifts, hospitality and benefits €177.8m

Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.

What organisations can take from it

Selecting speakers by prescription volume turns continuing education into bribery – selection criteria and hospitality limits must be documented.

Relevance to training and awareness

Fees and hospitality at professional events

Authority / court
U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)
Area of law
Bribery and corruption · Gifts, hospitality and benefits
Legal basis
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
Action
Other
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
29 Apr 2025

Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

24 Apr 2025 Johnson & Johnson Consumer NV; Boehringer Ingelheim SComm; Haleon Belgium NVJohnson & Johnson, Boehringer, Haleon: 11.2 million EUR for shelf-placement collusion in pharmacies BelgiumCartels and collusion €11.2m

Over more than 15 years, the three OTC medicine manufacturers jointly developed the category management project ‘SMAN’, through which they steered the placement of non-prescription medicines in selected pharmacies in their favour and disadvantaged or excluded competing products. In a settlement procedure, the Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (Belgian Competition Authority, BMA) imposed a total of 11,249,280.48 EUR.

What organisations can take from it

Category management agreements with retailers must not push competitors off the shelf – joint planograms with competitors are off limits.

Relevance to training and awareness

Competition law limits of category management

Authority / court
Autorité belge de la Concurrence / Belgische Mededingingsautoriteit (BMA)
Area of law
Competition law · Cartels and collusion
Legal basis
Code de droit économique Art. IV.1; AEUV Art. 101
Action
Fine
Status of proceedings
final
Sector
Chemicals and pharmaceuticals
Employees
10,000 or more
Published
24 Apr 2025

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

20 Jan 2025 Pharnext SAPharnext: FDA setbacks disclosed late and glossed over FranceDisclosure and reporting obligations €800,000

The biotech company did not disclose as soon as possible the FDA's request for an additional study on PXT-3003 and the subsequent rejection of an SPA application, and disseminated misleading communications to shareholders. Sanctions: Pharnext 500,000 EUR, former CEO Daniel Cohen 200,000 EUR, former CEO David Horn Solomon 100,000 EUR.

What organisations can take from it

Negative feedback from regulatory authorities is regularly inside information and must not be given a positive spin in letters to shareholders.

Authority / court
Autorité des marchés financiers (AMF), Commission des sanctions
Area of law
Capital markets and financial supervision · Disclosure and reporting obligations
Legal basis
Art. 17 MAR; Art. 12 Abs. 1 lit. c und Art. 15 MAR
Action
Fine
Status of proceedings
under appeal
Sector
Chemicals and pharmaceuticals
Liability of senior managers
Daniel Cohen (co-founder, directeur général until April 2020): 200,000 EUR; David Horn Solomon (directeur général from April 2020): 100,000 EUR
Sources

Checked against the official source on 25 Sep 2026 · Direct link

Report an error

Anonymous: we store only your text — no contact details and no IP address.

Load 5 more of 5

Ready for training that sticks?

Try it free for 14 days — from 1 user, no credit card, ends automatically.

Start free trial